| NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas MH Kulke, LB Anthony, DL Bushnell, WW De Herder, SJ Goldsmith, ... Pancreas 39 (6), 735-752, 2010 | 694 | 2010 |
| Consensus guidelines for the management and treatment of neuroendocrine tumors PL Kunz, D Reidy-Lagunes, LB Anthony, EM Bertino, K Brendtro, JA Chan, ... Pancreas 42 (4), 557-577, 2013 | 625 | 2013 |
| Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs DJ Kwekkeboom, J Mueller-Brand, G Paganelli, LB Anthony, S Pauwels, ... Journal of Nuclear Medicine 46 (1 suppl), 62S-66S, 2005 | 556 | 2005 |
| Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome J Rubin, J Ajani, W Schirmer, AP Venook, R Bukowski, R Pommier, ... Journal of Clinical Oncology 17 (2), 600-606, 1999 | 456 | 1999 |
| 90Y-edotreotide for metastatic carcinoid refractory to octreotide DL Bushnell Jr, TM O'Dorisio, MS O'Dorisio, Y Menda, RJ Hicks, ... Journal of Clinical Oncology 28 (10), 1652, 2010 | 381 | 2010 |
| Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies LB Anthony, EA Woltering, GD Espenan, MD Cronin, TJ Maloney, ... Seminars in nuclear medicine 32 (2), 123-132, 2002 | 359 | 2002 |
| Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome MH Kulke, D Hörsch, ME Caplin, LB Anthony, E Bergsland, K Öberg, ... Journal of clinical oncology 35 (1), 14-23, 2017 | 335 | 2017 |
| The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum LB Anthony, JR Strosberg, DS Klimstra, WJ Maples, TM O'Dorisio, ... Pancreas 39 (6), 767-774, 2010 | 320 | 2010 |
| Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a … LK Kvols, KE Oberg, TM O'Dorisio, P Mohideen, WW de Herder, R Arnold, ... Endocrine-related cancer 19 (5), 657-666, 2012 | 231 | 2012 |
| Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea JA Maroun, LB Anthony, N Blais, R Burkes, SD Dowden, G Dranitsaris, ... Current Oncology 14 (1), 13-20, 2007 | 208 | 2007 |
| Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced … P Hesketh, R Navari, T Grote, R Gralla, J Hainsworth, M Kris, L Anthony, ... Journal of Clinical Oncology 14 (8), 2242-2249, 1996 | 174 | 1996 |
| Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors JG Drougas, LB Anthony, TK Blair, RR Lopez, JK Wright Jr, WC Chapman, ... The American journal of surgery 175 (5), 408-412, 1998 | 173 | 1998 |
| Surgical treatment of advanced-stage carcinoid tumors: lessons learned JP Boudreaux, B Putty, DJ Frey, E Woltering, L Anthony, I Daly, ... Annals of surgery 241 (6), 839-846, 2005 | 150 | 2005 |
| From somatostatin to octreotide LAR: evolution of a somatostatin analogue L Anthony, PU Freda Current medical research and opinion 25 (12), 2989-2999, 2009 | 141 | 2009 |
| Somatostatin analogue phase I trials in neuroendocrine neoplasms L Anthony, D Johnson, K Hande, M Shaff, S Winn, M Krozely, J Oates Acta Oncologica 32 (2), 217-223, 1993 | 133 | 1993 |
| Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial M Pavel, DJ Gross, M Benavent, P Perros, R Srirajaskanthan, ... Endocrine-Related Cancer 25 (3), 309-322, 2018 | 131 | 2018 |
| Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease WD Denney, WE Kemp, LB Anthony, JA Oates, BF Byrd Journal of the American College of Cardiology 32 (4), 1017-1022, 1998 | 117 | 1998 |
| In situ radiotherapy with (111) In-penteteotide: State of the art and perspectives KE McCarthy, EA Woltering, LB Anthony The Quarterly Journal of Nuclear Medicine and Molecular Imaging 44 (1), 88, 2000 | 113 | 2000 |
| In situ radiotherapy with 111In-pentetreotide: initial observations and future directions. KE McCarthy, EA Woltering, GD Espenan, M Cronin, TJ Maloney, ... The Cancer Journal From Scientific American 4 (2), 94-102, 1998 | 110 | 1998 |
| Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors JT Kim, J Li, ER Jang, P Gulhati, PG Rychahou, DL Napier, C Wang, ... Carcinogenesis 34 (5), 953-961, 2013 | 95 | 2013 |
kulke mdana-farber cancer institute在 dfci.harvard.edu 的电子邮件经过验证
